Federico Cayol

Dr. Federico Cayol

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2020 in The Oncologist
Verified
Journal Article
Open access
PDF file
RPRafael Adrián Pacheco-Orozco
Rafael Adrián Pacheco-Orozco
LMLorena Montealegre-Páez
Lorena Montealegre-Páez
FCFederico Cayol
Federico Cayol
HGHéctor Martínez Gregorio
Héctor Martínez Gregorio
JOJavier Oliver
Javier Oliver
SPSandra Perdomo
Sandra Perdomo
Background Prostate cancer is the most incident and one of the deadliest male cancers in Latin America. Treatment for patients with metastatic castration‐resistant prostate cancer (mCRPC) includes androgen receptor signaling inhibitors (ARSi) such as abiraterone and enzalutamide, for which AR‐V7, an androgen receptor splice variant, has emerged as a biomarker for primary resistance. Our study sought to analyze the potential economic impact of the use of AR‐V7 detection as a treatment indicator in patients with mCRPC in 3 Latin American countries. Materials and methods A hypothetical cost prediction model for the use of non‐invasive Circulating Tumor Cell (CTC)‐based AR‐V7 testing as a treatment indicator for patients eligible for treatment with abiraterone/enzalutamide was conducted using available information on treatment and testing costs from Mexico, Argentina and Colombia. Results At an estimated prevalence of AR‐V7 positivity of 20%, the use of upfront AR‐V7 genetic testing resulted in annual net savings of $9,801,669.97, $6,390,055.75, and $3,096,780.91 in Mexico, Argentina and Colombia, respectively. A direct relationship between AR‐V7 positivity prevalence and net savings was found. Conclusion The use of a noninvasive AR‐V7 detection assay as a treatment indicator tool in patients eligible for treatment with Abiraterone or Enzalutamide in Latin America could be a cost‐effective approach for the management of these patients. Additional efforts are needed to accurately determine the incidence of castration‐resistant prostate cancer cases and the prevalence of AR‐V7 positivity in Latin‐America in order to predict the potential economic benefit of its clinical use. Implications for practice In Latin America, prostate cancer is the most frequently diagnosed cancer in men and the burden of this disease is expected to double in this region by 2030. Noninvasive detection of AR‐V7 is being currently validated as a predictive biomarker for benefit with ARSi therapy in patients with metastatic castration‐resistant prostate cancer (mCRPC). Our hypothetical cost saving analysis shows that AR‐V7 testing in peripheral blood of CRPC patients eligible for treatment with abiraterone or enzalutamide might represent a cost‐effective strategy to select patients who will benefit from AR‐axis directed treatment in 3 Latin American countries.

15 February 2021 in Oral and Maxillofacial Surgery
Verified
Journal Article
Closed access
PDF file
AYAlejandro Yanzon
Alejandro Yanzon
NGNatalia Lucia Gomez
Natalia Lucia Gomez
PPPedro Picco
Pedro Picco
LBLuis Boccalatte
Luis Boccalatte
FCFederico Cayol
Federico Cayol
MFMarcelo Figari
Marcelo Figari

Verified
Journal Article
Open access
PDF file
Agustina Ayelen SabaterAgustina Ayelen Sabater
Agustina Ayelen Sabater
PSPablo Sanchis
Pablo Sanchis
RSRocio Alejandra Seniuk
Rocio Alejandra Seniuk
GPGastón Mario Pascual
Gastón Mario Pascual
NANicolas Anselmino
Nicolas Anselmino
GGGeraldine Gueron
Geraldine Gueron
Prostate cancer (PCa) poses a significant global health challenge, particularly due to its progression into aggressive forms like neuroendocrine prostate cancer (NEPC). This study developed and validated a stemness-associated gene signature using advanced machine learning techniques, including Random Forest and Lasso regression, applied to large-scale transcriptomic datasets. The resulting seven-gene signature (KMT5C, DPP4, TYMS, CDC25B, IRF5, MEN1, and DNMT3B) was validated across independent cohorts and patient-derived xenograft (PDX) models. This signature demonstrated strong prognostic value for progression-free, disease-free, relapse-free, metastasis-free, and overall survival. Importantly, the signature not only identified specific NEPC subtypes, such as large-cell neuroendocrine carcinoma, which is associated with very poor outcomes, but also predicted a poor prognosis for PCa cases that exhibit this molecular signature, even when they were not histopathologically classified as NEPC. This dual prognostic and classifier capability makes the seven-gene signature a robust tool for personalized medicine, providing a valuable resource for predicting disease progression and guiding treatment strategies in PCa management.

15 December 2018 in Oncología Clínica
Verified
Journal Article
Open access
PDF file
VKVanesa Kazanietz
Vanesa Kazanietz
JSJésica Storino
Jésica Storino
JSJuan Pablo Santino
Juan Pablo Santino
PMPablo Pérez Mesa
Pablo Pérez Mesa
FCFederico Cayol
Federico Cayol
El adenocarcinoma hepatoide gástrico es un tumor maligno de baja incidencia, se describen asociados a aumento de alfa-fetoproteína y tienen pobre pronóstico. Se presenta el caso de un paciente de 44 años que en un contexto de síndrome de impregnación se evidencian múltiples lesiones hepáticas asociadas al aumento de alfa-fetoproteína. El diagnóstico y el tratamiento de estos tumores representan un desafío para el equipo médico.

15 April 2018 in Oncología Clínica
Verified
Journal Article
Open access
PDF file
IPInés Pucella
Inés Pucella
CGCecilia Gadan
Cecilia Gadan
MSMabel Sardi
Mabel Sardi
AJAna Del Valle Jaen
Ana Del Valle Jaen
MFMarcelo Figari
Marcelo Figari
FCFederico Cayol
Federico Cayol
Los carcinomas epidermoides de cabeza y cuello son un grupo poco frecuente de neoplasias, en los Estados Unidos representan aproximadamente el 3% de todos los tumores. El cáncer de cavum se diferencia de otros tumores de cabeza y cuello por su epidemiología, histología, historia natural y respuesta al tratamiento. Presenta una marcada variación geográfica debido a su etiología multifactorial. En las áreas endémicas, la incidencia y la mortalidad han disminuido en los últimos 30 años. Esto probablemente se deba a cambios en el estilo de vida y avances en la radioterapia (RT) y quimioterapia (QT) sistémica.

15 August 2017 in Oncología Clínica
Verified
Journal Article
Open access
PDF file
JLJuan Lacava
Juan Lacava
HCHéctor Cutuli
Héctor Cutuli
AOAndrea Odzak
Andrea Odzak
CNCarla Nicolini
Carla Nicolini
SDStella Drago
Stella Drago
VTVilma Tripodoro
Vilma Tripodoro
Durante los días 12 y 13 de mayo se llevó a cabo el Primer Congreso de Prevención y Genómica organizado por la Asociación Argentina de Oncología Clínica y que contó con los auspicios de 12 ONGs, 14 sociedades científicas (hechos inéditos en una actividad académica), organismos oficiales como el Instituto Nacional del Cáncer, Ministerios de Salud de las Provincias de Córdoba y Neuquén, y declarado de interés sanitario por la Legislatura Porteña.